Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid Leukemia

Clinical trial NCT03735875 · TERMINATED

Trial details

NCT number: NCT03735875
Sponsor: M.D. Anderson Cancer Center
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Acute Myeloid Leukemia With FLT3/ITD Mutation Recurrent Acute Myeloid Leukemia Refractory Acute Leukemia

Start date: 2019-01-25
Primary completion: 2023-07-26
Enrollment: 8

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.